ArticleAlzheimer's research & therapy2026
Literature-derived serum miRNA signatures associated with cognitive decline in Alzheimer's disease: integrated analysis and machine learning-based diagnostic modeling.
Article in Alzheimer's research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveBecause the clinical diagnosis of Alzheimer’s disease (AD) still relies largely on cognitive decline and A/T/N biomarkers remain costly and invasive, we aimed to identify literature-derived serum microRNAs (miRNAs) associated with cognitive function in AD and to re-evaluate them in a large public cohort (GSE120584) as potential adjunctive diagnostic biomarkers.
methodsWe systematically searched Chinese- and English-language databases for studies reporting serum miRNA expression in patients with AD and its association with cognitive scale scores. Functional target genes were retrieved from miRTarBase, protein–protein interaction (PPI) networks were constructed using STRING, and functional modules were identified with the Cytoscape plug-in MCODE. Enrichment analyses were then performed for Gene Ontology (GO), KEGG, Reactome, and Hallmark gene sets. Differential expression analysis of GSE120584 was conducted using limma, and partial correlations between miRNA expression and age, sex, and apolipoprotein E ε4 (APOE ε4) allele count were calculated. Based on the correlation structure and nested cross-validation, optimal miRNA combinations were selected, and multiple diagnostic models were developed using age and sex as baseline clinical predictors. Model performance was evaluated using receiver operating characteristic (ROC) and precision-recall (PR) curves, calibration curves, and decision curve analysis (DCA).
resultsTwenty-three publications including 2,458 patients with AD and 2,139 controls were ultimately included. Twenty-two differentially expressed serum miRNAs were identified, of which 15 were positively and 7 were negatively correlated with Mini-Mental State Examination (MMSE) scores. Target genes of positively correlated miRNAs were enriched in PI3K/AKT/mTOR, Wnt, and TNF-α/NF-κB signaling pathways, whereas target genes of negatively correlated miRNAs were mainly involved in cell cycle regulation, the G2/M checkpoint, and oxidative stress responses. After matching literature-derived miRNAs with GSE120584 and expanding the candidate miRNA set, 25 significantly differentially expressed miRNAs were identified. Correlation-network analysis combined with nested cross-validation indicated that the minimal miRNA signatures with optimal diagnostic value were miR-211-5p alone (K1) and the three-miRNA panel miR-211-5p, miR-128–1-5p, and miR-128-3p (K3). When age and sex were added, the “K3 + age + sex” model showed the best performance (area under the curve [AUC] = 0.838, average precision [AP] = 0.934, Brier score = 0.162), yielding the highest sensitivity (0.563) and the best positive predictive value (PPV = 0.954) at specificity ≥ 0.90.
conclusionBy integrating published evidence with re-evaluation in a public serum cohort, we found that adding miR-211-5p and a miR-128-related panel to age- and sex-based models provided a modest but consistent improvement in diagnostic discrimination for AD. These miRNAs may serve as adjunctive peripheral blood biomarkers, although their clinical utility requires confirmation in independent external cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.